2770-01-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-1H-imidazo[4,5-c]pyridine is used as a reagent for the synthesis of 3-bromo-3-deazaneplanocin and 3-bromo-3-deazaaristeromycin. These compounds exhibit antiviral activity, making them valuable in the development of new antiviral drugs to combat viral infections.
In the synthesis of these antiviral compounds, 4-chloro-1H-imidazo[4,5-c]pyridine plays a crucial role as a building block, contributing to the overall structure and activity of the final products. Its unique chemical properties allow for the formation of these biologically active molecules, which can be further optimized for improved efficacy and safety in treating viral diseases.

InChI:InChI=1/C6H4ClN3/c7-6-5-4(1-2-8-6)9-3-10-5/h1-3H,(H,9,10)

Upstream product

• 78582-15-7 4-chloro-1-(2'-deoxy-β-D-erythro-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 
• 129266-20-2 4-chloro-3-(2'-deoxy-β-D-erythro-pentofuranosyl)-3H-imidazo<4,5-c>pyridine 
• 39217-08-8 2-chloropyridine-3,4-diamine 
• 149-73-5 trimethyl orthoformate 
• 122-51-0 orthoformic acid triethyl ester 
• 14036-06-7 diethoxymethyl acetate 
• 3243-24-1 imidazo<4,5-c>pyridine-4-one 

Downstream Products

• 120537-46-4 4-chloro-3-(2-fluorobenzyl)-3H-imidazo<4,5-c>pyridine 
• 120537-45-3 4-chloro-1-(2-fluorobenzyl)-1H-imidazo<4,5-c>pyridine 
• 120537-44-2 3-benzyl-4-chloro-3H-imidazo<4,5-c>pyridine 
• 120537-43-1 1-benzyl-4-chloro-1H-imidazo<4,5-c>pyridine 
• 105522-24-5 3-((3aS,4R,6aR)-6-Benzyloxymethyl-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-yl)-4-chloro-3H-imidazo[4,5-c]pyridine 
• 105522-07-4 (-)-1-<(1R,4R,5S)-3-(Benzyloxymethyl)-4,5-O-isopropylidene-2-cyclopenten-1-yl>-4-chloroimidazo<4,5-c>pyridine 
• 130948-29-7 4-Chloro-3-<2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythropentofuranosyl>-1H-imidazo<4,5-c>pyridine 
• 78582-13-5 4-Chloro-1-<2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythropentofuranosyl>-1H-imidazo<4,5-c>pyridine 
• 120537-51-1 4-(dimethylamino)-1H-imidazo<4,5-c>pyridine 
• 50432-68-3 4-chloro-1-methyl-1H-imidazo(4,5-c)pyridine 
• 87034-78-4 4-chloro-3-methyl-3H-imidazo[4,5-c]pyridine 
• 80443-18-1 N-benzyl-1H-imidazo[4,5-c]pyridin-4-amine 
• 78582-15-7 4-chloro-1-(2'-deoxy-β-D-erythro-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 
• 120759-70-8 4-Chloro-1,3-dihydro-imidazo[4,5-c]pyridine-2-thione 

Relevant academic research and scientific papers

NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

This application describes a nitrogen heteroaryl derivative having CSF1R inhibitory activity, and a preparation method therefor and an application thereof. Compounds in the present invention has a structure represented by formula (I) as below, and the definition on substituents is as stated in the description and the claims. The compounds in the this application can be widely applied to preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease, or metastatic disease, in particular ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, metastasis of primary tumor sites, or osseous metastatic cancer, and a new generation of CSF1R inhibitor drugs is expected to be developed.

Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors

Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers. Consequently porcupine inhibitors are thought to be promising oncology therapeutics. A high throughput screen against porcupine revealed several potent hits that were confirmed to be Wnt pathway inhibitors in secondary assays. We developed a pharmacophore model and used the putative bioactive conformation of a xanthine inhibitor for scaffold hopping. The resulting maleimide scaffold was optimized to subnanomolar potency while retaining good physical druglike properties. A preclinical development candidate was selected for which extensive in vitro and in vivo profiling is reported.

Design and synthesis of purine analogues as highly specific ligands for FcyB, a ubiquitous fungal nucleobase transporter

In the course of our study on fungal purine transporters, a number of new 3-deazapurine analogues have been rationally designed, based on the interaction of purine substrates with the Aspergillus nidulans FcyB carrier, and synthesized following an effective synthetic procedure. Certain derivatives have been found to specifically inhibit FcyB-mediated [3H]-adenine uptake. Molecular simulations have been performed, suggesting that all active compounds interact with FcyB through the formation of hydrogen bonds with Asn163, while the insertion of hydrophobic fragments at position 9 and N6 of 3-deazaadenine enhanced the inhibition.

NOVEL CONDENSED IMIDAZOLE DERIVATIVE

Disclosed is a compound represented by the formula (1) below which has a high DPP-IV inhibitory activity and is improved in safety, toxicity and the like. Also disclosed is a prodrug of such a compound and pharmaceutically acceptable salts of them. (In the formula, R1 represents a hydrogen atom, an optionally substituted alkyl group or the like; R2 and R3 independently represent a hydrogen atom, an optionally substituted alkyl group or the like; R4 and R5 independently represent a hydrogen atom, an optionally substituted alkyl group or the like: R6 represents a hydrogen atom, an optionally substituted aryl group or the like; and -Y-NH2, represents a group represented by the following formula (A): (wherein m is 0, 1 or 2; and R7 may not exist or one or two R7 may exist and independently represent an optionally substituted alkyl group or the like) or the like.]